Autolus Therapeutics plc (AUTL) Form 8-K — Aug 3, 2026
Autolus Therapeutics plc entered into a secured notes facility with Perceptive Credit Holdings V, LP to raise up to $250.0 million in aggregate principal, issuing $75.0 million in the first tranche immediately. The facility includes additional tranches available through 2030, contingent on revenue milestones, and matures on July 30, 2031. The debt carries a high interest rate equal to one-month term SOFR or a 3.50% floor plus an applicable margin of 6.75% to 7.25%. The company’s obligations are secured by a first-priority lien on substantially all of its assets and guaranteed by major subsidiaries, including Autolus Limited and Autolus Inc.
Key figures
- Debt Amount
- 250000000
- Interest Rate
- 6.75% - 7.25% + SOFR (floor 3.50%)
- Maturity Date
- 2031-07-30
- Gross Proceeds
- 75000000
- Tranche1 issued
- $75.0 million
- Tranche2 available
- $25.0 million
- Tranche3 available
- $75.0 million
- Tranche4 available
- $75.0 million
- Warrants on tranche 3
- 2500000
- Warrants on tranche 4
- 2500000
- Warrant exercise price
- $1.9314
- Warrant shares initial
- 3500000
- Liquidity covenant range
- $12.5 million - $50.0 million
Price after filing
Close on the filing date to close N calendar days later (from $1.82). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.